Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for NEXAVAR
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Safety, Tolerability and Anti-tumour Activity Study of MTL-CEBPA Plus Sorafenib
- The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
- SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
- Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
- Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers
- Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
- SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
- Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
- Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
- Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
- Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
- Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
- Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
- Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
- Circulating Tumor Cells and Tumor DNA in HCC and NET
- Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
- Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
- Metformin Plus Sorafenib for Advanced HCC
- Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
- 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
- Bioequivalence Study of Sorafenib Tablet and Nexavar
- MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
- Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
- Trial of TRC105 and Sorafenib in Patients With HCC
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
- Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
- Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
- A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
- Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
- Epigenetic Reprogramming in Relapse AML
- Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
- Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
- Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
- Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
- Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
- Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
- A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
- Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
- Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
- Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Second Line Sorafenib After Pazopanib in Patients With RCC
- Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
- Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
- Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Sorafenib for Hepatopulmonary Syndrome
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
- Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
- Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
- Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
- Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
- Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC
- Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
- Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
- Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
- Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
- Sorafenib + mFOLFOX for Hepatocellular Carcinoma
- Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
- A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
- Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
- Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
- Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
- Study of Curcumin, Vorinostat, and Sorafenib
- Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
- Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
- Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
- Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
- Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
- Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
- Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
- Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
- Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
- Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
- Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
- Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
- Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
- Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
- Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
- Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
- Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
- Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer
- Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
- Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
- Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
- A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
- A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
- Sorafenib and TRC105 in Hepatocellular Cancer
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
- Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer
- Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
- Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
- Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
- Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
- Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
- GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
- Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
- Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
- Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
- Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
- Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
- Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
- Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
- Sorafenib Plus S-1 in Advanced Solid Tumors
- Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
- Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
- Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
- Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
- CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
- Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
- AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Regulatory Post Marketing Surveillance Study on Nexavar®
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
- Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
- Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
- Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
- Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
- Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
- Depocyt® With Sorafenib in Neoplastic Meningitis
- Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
- Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
- Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
- Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
- Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
- Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
- Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
- Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
- Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
- Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
- Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer
- Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
- Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
- Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
- Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
- Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
- Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
- Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
- Sorafenib and Dacarbazine in Soft Tissue Sarcoma
- Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
- Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- Study of Sorafenib/Cetuximab in Head and Neck Cancer
- Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
- Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
- Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
- INSIGHT - Post Marketing Surveillance
- Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
- Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
- A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
- Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
- A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
- Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
- PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
- Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
- Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
- Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
- Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
- Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
- Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
- Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
- Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
- Sorafenib Long Term Extension Program
- Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
- Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
- Sorafenib Dose Escalation in Renal Cell Carcinoma
- TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
- Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
- A Study of Radiation With Sorafenib in Advanced Cancer
- Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
- A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
- Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
- Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
- Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
- PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
- Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
- Treatment of Advanced Renal Cell Carcinoma With Quinacrine
- Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
- Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
- Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
- Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
- Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
- Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
- Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
- Sorafenib in Resected Non-small Cell Lung Carcinoma
- Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
- Sorafenib in Myelodysplastic Syndrome
- Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
- Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
- Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
- Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
- Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
- Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
- Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
- Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
- Sorafenib in Treating Patients With Advanced Solid Tumors
- Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
- Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
- Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
- Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
- Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
- Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
- Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
- Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
- Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
- Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
- Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
- Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
- S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
- Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
- Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
- Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
- Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
- Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
- Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
- Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
- Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
- Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
- Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006
- Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
- Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
- Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
- Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
- Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
- Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
- Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
- Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
- Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
- Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
- Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Clinical trials list
click for details